Agios Pharmaceuticals (NASDAQ:AGIO) Trading Down 7.5% - Should You Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) dropped 7.5% during trading on Friday . The company traded as low as $33.06 and last traded at $33.22. Approximately 99,557 shares traded hands during mid-day trading, a decline of 90% from the average daily volume of 1,016,120 shares. The stock had previously closed at $35.90.

Analyst Ratings Changes

A number of analysts recently weighed in on AGIO shares. Raymond James reiterated an "outperform" rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Scotiabank raised their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a "sector outperform" rating in a research note on Monday, December 9th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Finally, Leerink Partners cut Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $56.33.

Agios Pharmaceuticals Stock Down 4.1 %

The firm's 50-day moving average is $46.77 and its two-hundred day moving average is $45.50. The stock has a market cap of $1.96 billion, a P/E ratio of 3.03 and a beta of 0.87.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.93% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at $37,000. Quest Partners LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth about $40,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC increased its holdings in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock valued at $96,000 after acquiring an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals in the 3rd quarter worth about $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.